Top Page
Vaxart
(OTC:VXRT)
Vaxart (VXRT) vs. SPDR S&P 500 ETF (SPY)
Vaxart Business Overview & Revenue Model
Vaxart Earnings Call Summary
Vaxart Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.72M | 28.70M | 7.38M | 107.00K | 892.00K | 4.05M |
| Gross Profit | 80.72M | 28.70M | 2.88M | -80.95M | -47.86M | -15.82M |
| EBITDA | -44.20M | -54.87M | -72.13M | -103.12M | -66.45M | -28.26M |
| Net Income | -56.64M | -66.95M | -82.47M | -107.76M | -70.47M | -32.22M |
Balance Sheet | ||||||
| Total Assets | 164.09M | 166.39M | 91.83M | 153.85M | 221.17M | 152.58M |
| Cash, Cash Equivalents and Short-Term Investments | 26.27M | 51.72M | 39.71M | 93.72M | 166.49M | 126.87M |
| Total Debt | 16.11M | 23.28M | 26.51M | 27.42M | 24.53M | 22.14M |
| Total Liabilities | 131.21M | 107.46M | 34.02M | 43.25M | 33.64M | 29.18M |
| Stockholders Equity | 32.88M | 58.92M | 57.80M | 110.60M | 187.53M | 123.40M |
Cash Flow | ||||||
| Free Cash Flow | -37.17M | -45.32M | -72.32M | -104.38M | -64.99M | -24.97M |
| Operating Cash Flow | -37.09M | -44.76M | -70.45M | -94.78M | -59.83M | -23.75M |
| Investing Cash Flow | 13.83M | -21.32M | 43.95M | -20.41M | -49.10M | -1.22M |
| Financing Cash Flow | 87.00K | 56.56M | 15.24M | 17.46M | 125.80M | 138.31M |
Vaxart Technical Analysis
Vaxart Risk Analysis
Vaxart Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $116.93M | ― | -69.71% | ― | 303.47% | 73.70% | |
| ― | $107.48M | ― | -49.55% | ― | -33.76% | 17.10% | |
| ― | $283.35M | ― | -37.89% | ― | -100.00% | -62.44% | |
| ― | $80.12M | ― | -100.35% | ― | 479.58% | 46.15% | |
| ― | $204.49M | ― | -313.82% | ― | 41.61% | -17.39% | |
| ― | $82.86M | ― | -208.93% | ― | ― | 35.46% |
Vaxart Corporate Events
On August 5, 2025, Vaxart received a stop work order for its Project Agreement under the Consortium Base Agreement with ATI, funded by BARDA. Despite this, the company can continue follow-up efforts for a Phase 2b study involving its oral COVID-19 vaccine candidate. On October 8, 2025, a follow-up notice clarified that BARDA intends to exclude the paused work from the Project Agreement, but Vaxart will still receive funding for evaluating the trial’s 5,000 participants. The company believes the trial data will provide valuable insights and support for advancing its COVID program.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Vaxart, Inc. faced a delisting from Nasdaq after failing to meet the conditions set by the Nasdaq Hearings Panel, which included obtaining shareholder approval and completing a reverse stock split by specified dates in 2025. Consequently, Vaxart’s common stock was suspended from trading on Nasdaq and is now quoted on the OTCQX Best Market under the symbol ‘VXRT’.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Vaxart, Inc. had planned a special meeting of stockholders on September 5, 2025, which was adjourned to September 19, 2025, to allow more time for voting on a proposal. However, on September 18, 2025, the company decided to withdraw the proposal and will not reconvene the meeting, indicating a shift in their strategic decisions.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On September 5, 2025, Vaxart, Inc. adjourned its special meeting of stockholders to provide additional time for voting on proposals, including a reverse stock split. The meeting will reconvene on September 19, 2025, and during the adjournment, Vaxart will continue soliciting votes. This decision reflects recent changes in board composition and governance considerations, highlighting the company’s strategic focus on maintaining its Nasdaq listing and engaging with stockholders to maximize value.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On September 2, 2025, Vaxart announced the retirement of Michael J. Finney, Ph.D., from its Board of Directors, effective September 30, 2025. Dr. Finney’s departure, due to personal reasons, led to a reduction in the board size from six to five members. His leadership and contributions were acknowledged as pivotal to Vaxart’s growth and mission. The board plans to meet to discuss future leadership and governance, aiming to continue advancing the company’s scientific progress.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
The recent earnings call for Vaxart painted a picture of both optimism and caution. The company reported strong financial growth and promising vaccine development results, but also faced significant challenges, including a stop work order on a major trial and issues with stock listing compliance. This mix of positive advancements and operational uncertainties created a balanced sentiment during the call.
On August 27, 2025, Vaxart received a decision from the Nasdaq Hearings Panel allowing the company to continue its listing on Nasdaq, contingent upon meeting specific conditions including a reverse stock split by October 17, 2025. This decision follows a period of non-compliance with Nasdaq’s minimum bid price requirement, and the company is actively engaging with stockholders to secure their support for the necessary actions to maintain its listing, which is critical for its future success in the competitive vaccine industry.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On August 20, 2025, Vaxart, Inc. held a virtual fireside chat with stockholders to discuss a proposed reverse stock split and its implications for the company’s NASDAQ listing. The management emphasized the importance of maintaining a NASDAQ listing for increased visibility, liquidity, and access to capital, which are crucial for advancing their vaccine development programs. The reverse stock split is seen as a strategic move to enhance the company’s market position and protect stockholder investments, with advisory firms ISS and Glass Lewis recommending support for the proposal.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
On August 14, 2025, Vaxart announced a virtual stockholder fireside chat scheduled for August 20, 2025, to discuss a reverse stock split proposal. Supported by proxy advisory firms ISS and Glass Lewis, the proposal aims to regain Nasdaq compliance. The event will allow stockholders to engage directly with Vaxart’s management and address frequently asked questions.
The most recent analyst rating on (VXRT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform, targeting diseases such as coronavirus, norovirus, and influenza. In its latest earnings report for the second quarter of 2025, Vaxart highlighted significant progress in its vaccine development programs, including positive topline data from its Phase 1 clinical trial for a second-generation oral norovirus vaccine and substantial enrollment in its COVID-19 Phase 2b trial before a stop work order was issued. The company reported a revenue increase to $39.7 million, primarily from government contracts, and a net loss of $15.0 million, showing an improvement from the previous year. Vaxart’s research and development expenses rose significantly due to ongoing clinical trials, while general and administrative expenses decreased. Looking ahead, Vaxart plans to continue advancing its vaccine candidates through clinical trials, with a focus on securing partnerships and funding to extend its cash runway and achieve regulatory milestones.